Search PubMed⌕ Search

Biomedical subjects

L Hansson

Publications and source records attributed to L Hansson.

At least 487 records · Page 27Linked to original sources
PubMed1978

Coronary heart-disease after treatment of hypertension.

Within a group of 1026 men aged 47-54, cause-specific death-rates and the incidence of non-fatal myocardial infarction and stroke in treatment group of 635 hypertensive men (casual systolic B.P. greater than 175 or diastolic B.P. greater than 115 mm Hg on two occasions) treated at a hypertension clinic were compared with those in a control group of 391 men (causal systolic B.P. greater than 175 or diastolic greater than 115 mm Hg on only one occasion) who remained mainly untreated during their 4.3 years of follow-up. The predicted risk of coronary heart-disease (C.H.D.) at entry, calculated by a multiple logistic function, was slightly higher in the treatment group. Total death-rate during follow-up was significantly lower in the treatment group (3.3%) than in the control group (6.1%). The difference in death-rate for C.H.D. was of the same relative order (0.8% versus 1.5%), as was the incidence of non-fatal myocardial infarction (2.8% versus 5.4%), although none of the differences reached statistical significance. However, the pooled incidence of fatal and non-fatal C.H.D. was significantly lower in the treatment group (3.6%) than in the control group (6.9%). The results suggest that antihypertensive treatment might be effective in preventing or postponing C.H.D. in middle-aged men.

Cerebrovascular Disorders↗
PubMed1977

Controlled trial of acebutolol in hypertension.

Acebutolol, a new cardioselective beta-adrenoceptor blocking agent, has been evaluated for the treatment of hypertension. Thirty eight previously untreated male patients with essential hypertension received placebo treatment during a 4-week run-in period, and then they were randomly (double-bind) allocated either to continued placebo treatment for three 4-week periods or to treatment with acebutolol 400, 600, and 1200 mg daily, respectively, for three 4-week periods. Blood pressure and heart rate were recorded at the end of each 4-week period. Treatment with acebutolol produced statistically significant reductions in blood pressure and heart rate as compared to the placebo regimen.

Acebutolol↗
PubMed1977

Prolonged exposure to a stressful stimulus (noise) as a cause of raised blood-pressure in man.

Systolic and diastolic blood-pressure was significantly higher in 44 male industrial workers with a noise-induced auditory impairment (greater than or equal to 65 dB at 3000, 4000, or 6000 Hz) than in 74 males of the same age with normal hearing. Moreover, significantly more individuals with hypertension (resting recumbent blood-pressure greater than or equal to 160/100 mm Hg) were found in the group with noise-induced loss of hearing. It is suggested that replaced and prolonged exposure to a stressful stimulus (industrial noise severe and prolonged enough to cause a permanent loss of hearing at the relevant frequencies) may be a contributing factor to the rise in blood-pressure through a mechanism involving structural adaption of blood-vessels in response to repeated peaks of raised blood-pressure.

Adult↗
PubMed1976

A comparison of the antihypertensive effect of atenolol (ICI 66 082) and propranolol.

Propranolol was given to 30 patients with essential hypertension following randomised, double-blind administration of either placebo or a new cardioselective beta-adrenergic receptor antagonist, atenolol (Tenormin, ICI 66 082). Both atenolol and propranolol caused statistically significant reduction of recumbent and erect blood pressure and heart rate. There were no important differences between these variables on comparison of atenolol and propranolol.

Adolescent↗